{"id":"NCT03461757","sponsor":"Pfizer","briefTitle":"Trial in Adult Subjects With Acute Migraines","officialTitle":"BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-02-27","primaryCompletion":"2018-10-08","completion":"2018-10-15","firstPosted":"2018-03-12","resultsPosted":"2020-03-27","lastUpdate":"2023-02-16"},"enrollment":1811,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine, With or Without Aura"],"interventions":[{"type":"DRUG","name":"Rimegepant","otherNames":["BHV-3000"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Arm 1: Rimegepant 75 mg","type":"EXPERIMENTAL"},{"label":"Arm 2: Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant ODT) versus placebo in subjects with Acute Migraines.","primaryOutcome":{"measure":"Percentage of Participants With Freedom From Pain at 2 Hours Post-dose","timeFrame":"2 hours post-dose","effectByArm":[{"arm":"Rimegepant 75 mg ODT","deltaMin":21.2,"sd":null},{"arm":"Placebo","deltaMin":10.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":69,"countries":["United States"]},"refs":{"pmids":["36739511","36125279","31311674"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":682},"commonTop":[]}}